1. Home
  2. AKBA vs AAOI Comparison

AKBA vs AAOI Comparison

Compare AKBA & AAOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKBA
  • AAOI
  • Stock Information
  • Founded
  • AKBA 2007
  • AAOI 1997
  • Country
  • AKBA United States
  • AAOI United States
  • Employees
  • AKBA N/A
  • AAOI N/A
  • Industry
  • AKBA Biotechnology: Pharmaceutical Preparations
  • AAOI Semiconductors
  • Sector
  • AKBA Health Care
  • AAOI Technology
  • Exchange
  • AKBA Nasdaq
  • AAOI Nasdaq
  • Market Cap
  • AKBA 861.7M
  • AAOI 950.4M
  • IPO Year
  • AKBA 2014
  • AAOI 2013
  • Fundamental
  • Price
  • AKBA $2.82
  • AAOI $29.47
  • Analyst Decision
  • AKBA Strong Buy
  • AAOI Buy
  • Analyst Count
  • AKBA 5
  • AAOI 6
  • Target Price
  • AKBA $6.90
  • AAOI $28.40
  • AVG Volume (30 Days)
  • AKBA 3.6M
  • AAOI 5.1M
  • Earning Date
  • AKBA 11-06-2025
  • AAOI 11-06-2025
  • Dividend Yield
  • AKBA N/A
  • AAOI N/A
  • EPS Growth
  • AKBA N/A
  • AAOI N/A
  • EPS
  • AKBA N/A
  • AAOI N/A
  • Revenue
  • AKBA $203,733,000.00
  • AAOI $368,233,000.00
  • Revenue This Year
  • AKBA $43.91
  • AAOI $91.13
  • Revenue Next Year
  • AKBA $32.09
  • AAOI $55.88
  • P/E Ratio
  • AKBA N/A
  • AAOI N/A
  • Revenue Growth
  • AKBA 16.75
  • AAOI 77.94
  • 52 Week Low
  • AKBA $1.24
  • AAOI $9.71
  • 52 Week High
  • AKBA $4.08
  • AAOI $44.50
  • Technical
  • Relative Strength Index (RSI)
  • AKBA 34.99
  • AAOI 64.13
  • Support Level
  • AKBA $2.91
  • AAOI $27.30
  • Resistance Level
  • AKBA $3.02
  • AAOI $29.80
  • Average True Range (ATR)
  • AKBA 0.13
  • AAOI 2.02
  • MACD
  • AKBA -0.01
  • AAOI 0.62
  • Stochastic Oscillator
  • AKBA 0.00
  • AAOI 92.76

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About AAOI Applied Optoelectronics Inc.

Applied Optoelectronics Inc is a provider of fiber-optic networking products, for four networking end-markets; internet data center, CATV, telecom, and FTTH. The Company designs and manufactures a wide range of optical communications products at varying levels of integration, from components, subassemblies, and modules to complete turn-key equipment. Through direct sales personnel, and manufacturing teams in the United States, China, and Taiwan, the company coordinates with customers to determine product design, qualifications, and performance. The Company has manufacturing and research and development facilities located in the U.S., Taiwan, and China.

Share on Social Networks: